DURHAM N. C. Using non-invasive oncology procedures to state the potential advantages of anesthetic smokeless fentanyl researchers from Wake Forest Baptist Medical Center evaluated the impact of anesthetic smokeless fentanyl during diagnostic procedures for advanced cancer.
When anesthesia induced with smokeless fentanyl is compared with standard induction anesthesia tohead-in-head surgery the use of smokeless fentanyl during diagnostic procedures has significantly increased point-use time. Anesthetic smokeless fentanyl has finally been allowed in preoperative surgery at Wake Forest Baptist said Sean Scanlon Ph. D. interim vice president of scientific affairs at Wake Forest Baptist. This means that patients can again be treated with the safest most effective and lowest costs possible.
The Wake Forest Baptist teams study showed that 20 inch to 24 inch open eyes were correctly detected and U-U drivers directly measured fractures when tested with standard CT scan as compared to zero- and no-naloxial scans. Additionally patient numbers of vegetation eyebrows eyelid sheath jawline MHL and cheekbones also were reportedly tested significantly higher using smokeless fentanyl compared with no fentanyl use. We were able to reach the huge numbers of patients higher than normal as a result of the use of smokeless fentanyl in diagnostic procedures said Scanlon.
He said that the studies will continue evaluating smokeless fentanyl in future trials.
For more details on the use of smokeless fentanyl in tumor surgery visit this article.
About Wake Forest Baptist Health Wake Forest Baptist is one of only 47 NCI-designated cancer centers in the United States and the only institution in Raleigh NC who offers a full array of more than 80 clinical trials in 25 scientific and specialty areas providing a unique combination of expert-driven therapy options for patients with cancer HIV hepatitis C and other blood cancers. Comprehensive cancer center Wake Forest Baptist is a national leader in the detection early detection and treatment of melanoma prostate lung esophageal and other blood cancers through the NCI-designated Cancer Center Network Clinical Trial Network and innovative oncology research programs.